Acalabrutinib Plus Rituximab “Highly Effective” in Older MCL Patients
Acalabrutinib and rituximab can yield early complete responses in older patients with previously untreated mantle cell lymphoma.
Diagnosis & Disease Information
Risk-Adapted Treatment Approach Produces Durable Remissions in MCL
A risk-adapted treatment approach can produce durable responses in younger patients with mantle cell lymphoma, a phase 2 trial suggests.
Pirtobrutinib Produces Durable Responses in Relapsed/Refractory MCL
Pirtobrutinib has shown clinical activity in a phase 1/2 trial of patients with relapsed or refractory mantle cell lymphoma.
Ibrutinib No Longer Approved for MCL, MZL: How This Change Will Affect Patients
The withdrawn approvals of ibrutinib for relapsed/refractory MCL and MZL are likely to have a limited impact on patients, experts say.
Bispecific CAR T-Cell Therapy Has “Robust” Activity in Non-Hodgkin Lymphoma
A bispecific CAR T-cell therapy produced responses in 91% of patients with relapsed/refractory non-Hodgkin lymphoma in a phase 1 trial.
Imbruvica No Longer Approved to Treat MCL, MZL in the US
AbbVie and Janssen are withdrawing the accelerated approvals of Imbruvica for mantle cell lymphoma and marginal zone lymphoma.
Jaypirca Approved for Relapsed/Refractory Mantle Cell Lymphoma
As a noncovalent inhibitor of BTK, pirtobrutinib is able to reestablish BTK inhibition in patients previously treated with covalent BTK inhibitors.
ASH 2022: MCL Trials Break New Ground, May Change Practice
Mantle cell lymphoma trials presented at ASH 2022 have broken new ground, shown promising results, and may change practice, according to researchers.
Adding Ibrutinib to Induction and Maintenance Improves FFS in Mantle Cell Lymphoma
Adding ibrutinib to induction and maintenance after transplant improves failure-free survival in patients with mantle cell lymphoma, results of the TRIANGLE study suggest.
Zandelisib Plus Zanubrutinib Elicits High ORRs in Relapsed/Refractory FL or MCL
The combination of zandelisib and zanubrutinib produced high overall response rates in patients with relapsed/refractory follicular lymphoma or mantle cell lymphoma.
- Loading...
Loading...
Next post in ASH 2022
Loading... 
Loading...